Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis

BACKGROUND: Ixekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab’s potential to induce and exacerbate inflammatory bowel disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Xin, Fardy, John, Reid, Stephanie, Trahey, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487480/
https://www.ncbi.nlm.nih.gov/pubmed/34600483
http://dx.doi.org/10.1186/s12876-021-01936-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487480/
https://www.ncbi.nlm.nih.gov/pubmed/34600483
http://dx.doi.org/10.1186/s12876-021-01936-w

Ejemplares similares